Tolulope T Sajobi1, Bijoy K Menon1, Meng Wang1, Oluwaseyi Lawal1, Ashfaq Shuaib1, David Williams1, Alexandre Y Poppe1, Tudor G Jovin1, Leanne K Casaubon1, Thomas Devlin1, Dar Dowlatshahi1, Chris Fanale1, Mark W Lowerison1, Andrew M Demchuk1, Mayank Goyal1, Michael D Hill2. 1. From the Department of Community Health Sciences and O'Brien Institute for Public Health (T.T.S., B.K.M., M.W.L., M.D.H.), Department of Clinical Neurosciences (T.T.S., B.K.M., M.W., A.M.D., M.G., M.D.H.), Hotchkiss Brain Institute (T.T.S., B.K.M., A.M.D., M.G., M.D.H.), Department of Radiology (B.K.M., A.M.D., M.G., M.D.H.), Clinical Research Unit (T.T.S., B.K.M., M.W.L., M.D.H.), Department of Physiology and Pharmacology (O.L.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Royal College of Physicians in Ireland and Beaumont Hospital, Dublin, Ireland (D.W.); Department of Clinical Neurosciences, Universite de Montreal and Hopital Notre Dame, Quebec, Canada (A.Y.P.); University of Pittsburgh Medical Centre, PA (T.G.J.); University Health Network and Toronto Western Hospital, Ontario, Canada (L.K.C.); Erlanger Medical Center, Chattanooga, TN (T.D.); University of Ottawa Hospital, Ontario, Canada (D.D.); and Swedish Medical Centre, Englewood, CO (C.F.). 2. From the Department of Community Health Sciences and O'Brien Institute for Public Health (T.T.S., B.K.M., M.W.L., M.D.H.), Department of Clinical Neurosciences (T.T.S., B.K.M., M.W., A.M.D., M.G., M.D.H.), Hotchkiss Brain Institute (T.T.S., B.K.M., A.M.D., M.G., M.D.H.), Department of Radiology (B.K.M., A.M.D., M.G., M.D.H.), Clinical Research Unit (T.T.S., B.K.M., M.W.L., M.D.H.), Department of Physiology and Pharmacology (O.L.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Division of Neurology, University of Alberta, Edmonton, Alberta, Canada (A.S.); Royal College of Physicians in Ireland and Beaumont Hospital, Dublin, Ireland (D.W.); Department of Clinical Neurosciences, Universite de Montreal and Hopital Notre Dame, Quebec, Canada (A.Y.P.); University of Pittsburgh Medical Centre, PA (T.G.J.); University Health Network and Toronto Western Hospital, Ontario, Canada (L.K.C.); Erlanger Medical Center, Chattanooga, TN (T.D.); University of Ottawa Hospital, Ontario, Canada (D.D.); and Swedish Medical Centre, Englewood, CO (C.F.). michael.hill@ucalgary.ca.
Abstract
BACKGROUND AND PURPOSE: The trajectory of neurological improvement after stroke treatment is clinically likely to be an important prognostic signal. We compared the accuracy of early longitudinal National Institutes of Health Stroke Scale (NIHSS) measurement versus other early markers of stroke severity post treatment in predicting subjects' 90-day stroke outcome. METHODS: Data are from the Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with ESCAPE trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). Stroke severity was assessed at baseline, 1, 2, 5, 30, and 90 days. Subjects' functional outcome was assessed using the modified Rankin Scale at baseline, 30 days, and 90 days. Group-based trajectory model was used to identify distinct subgroups of longitudinal trajectories of NIHSS measured over the first 2, 5, and 30 days. The accuracy of baseline NIHSS, infarct volume, 24-hour change in NIHSS, infarct volume, and disease severity trajectory subgroups in predicting 90-day stroke outcome were assessed using logistic regression analysis. RESULTS: Group-based trajectory model of the 2-day longitudinal NIHSS data revealed 3 distinct subgroups of NIHSS trajectories-large improvement (41.6%), minimal improvement (31.1%), and no improvement (27.3%) subgroups. Individuals in the large improvement group were more likely were more likely to exhibit good outcomes after 90 days than those in the minimal improvement or no improvement subgroup. Among candidate predictors, the 2-day trajectory subgroup variable was the most accurate in predicting 90-day modified Rankin Scale at 84.5%. CONCLUSIONS: Early trajectory of neurological improvement defined by 2-day longitudinal NIHSS data predicts functional outcomes with greater accuracy than other common variables. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01778335.
RCT Entities:
BACKGROUND AND PURPOSE: The trajectory of neurological improvement after stroke treatment is clinically likely to be an important prognostic signal. We compared the accuracy of early longitudinal National Institutes of Health Stroke Scale (NIHSS) measurement versus other early markers of stroke severity post treatment in predicting subjects' 90-day stroke outcome. METHODS: Data are from the Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with ESCAPE trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times). Stroke severity was assessed at baseline, 1, 2, 5, 30, and 90 days. Subjects' functional outcome was assessed using the modified Rankin Scale at baseline, 30 days, and 90 days. Group-based trajectory model was used to identify distinct subgroups of longitudinal trajectories of NIHSS measured over the first 2, 5, and 30 days. The accuracy of baseline NIHSS, infarct volume, 24-hour change in NIHSS, infarct volume, and disease severity trajectory subgroups in predicting 90-day stroke outcome were assessed using logistic regression analysis. RESULTS: Group-based trajectory model of the 2-day longitudinal NIHSS data revealed 3 distinct subgroups of NIHSS trajectories-large improvement (41.6%), minimal improvement (31.1%), and no improvement (27.3%) subgroups. Individuals in the large improvement group were more likely were more likely to exhibit good outcomes after 90 days than those in the minimal improvement or no improvement subgroup. Among candidate predictors, the 2-day trajectory subgroup variable was the most accurate in predicting 90-day modified Rankin Scale at 84.5%. CONCLUSIONS: Early trajectory of neurological improvement defined by 2-day longitudinal NIHSS data predicts functional outcomes with greater accuracy than other common variables. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01778335.
Authors: D Sacks; B Baxter; B C V Campbell; J S Carpenter; C Cognard; D Dippel; M Eesa; U Fischer; K Hausegger; J A Hirsch; M S Hussain; O Jansen; M V Jayaraman; A A Khalessi; B W Kluck; S Lavine; P M Meyers; S Ramee; D A Rüfenacht; C M Schirmer; D Vorwerk Journal: AJNR Am J Neuroradiol Date: 2018-05-17 Impact factor: 3.825
Authors: Mark R Etherton; Ona Wu; Anne-Katrin Giese; Arne Lauer; Gregoire Boulouis; Brittany Mills; Lisa Cloonan; Kathleen L Donahue; William Copen; Pamela Schaefer; Natalia S Rost Journal: Transl Stroke Res Date: 2019-01-28 Impact factor: 6.829
Authors: Laura Ibanez; Laura Heitsch; Umber Dube; Fabiana H G Farias; John Budde; Kristy Bergmann; Rich Davenport; Joseph Bradley; Caty Carrera; Janne Kinnunen; Hanne Sallinen; Daniel Strbian; Agnieszka Slowik; Israel Fernandez-Cadenas; Joan Montaner; Jin-Moo Lee; Carlos Cruchaga Journal: Stroke Date: 2019-05-14 Impact factor: 7.914
Authors: Ruchira M Jha; Jonathan Elmer; Benjamin E Zusman; Shashvat Desai; Ava M Puccio; David O Okonkwo; Seo Young Park; Lori A Shutter; Jessica S Wallisch; Yvette P Conley; Patrick M Kochanek Journal: Crit Care Med Date: 2018-11 Impact factor: 7.598
Authors: Ana Lima Silva; Ana Sofia Pessoa; Renato Nogueira; José Manuel Araújo; José Nuno Alves; João Pinho; Carla Ferreira Journal: Neurol Sci Date: 2019-11-11 Impact factor: 3.307
Authors: Luuk Dekker; Victor J Geraedts; Hajo Hund; Suzanne C Cannegieter; Raul G Nogueira; Mayank Goyal; Ido R van den Wijngaard Journal: Interv Neurol Date: 2018-01-25